Almirall and Absci partner to develop AI-designed therapeutics for dermatological diseases

Almirall S.A., a global biopharmaceutical company focused on medical dermatology, and Absci Corporation, a generative AI drug creation company, today announced a drug discovery partnership aimed to develop and commercialize AI-designed therapeutics to fight chronic and debilitating dermatological diseases. The partnership combines Absci’s Integrated Drug Creation™ platform with Almirall’s dermatological expertise with the goal of delivering life-changing medicines to patients, marking another step forward in AI drug creation.

Talc claimants file class action suit accusing J&J of fraud over bankruptcy moves

As Johnson & Johnson attempts to settle tens of thousands of talc lawsuits, a group of five plaintiffs filed new litigation on Tuesday accusing the

May 24, 2024

Latest data shows millions of eligible Americans have been disenrolled from Medicaid

More than 10 million people were disenrolled from Medicaid over the past six months, according to the latest data published by a KFF tracker. The

November 3, 2023

Pfizer’s multiple myeloma treatment secures conditional approval in EU – Pharmaceutical Technology

Share this article The approval means the treatment will be available across all 27 EU member states. Credit: Shutterstock / Karolis Kavolelis. Pfizer’s Elrexfio for

December 8, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.